Articles with public access mandates - Guillaume CartronLearn more
Not available anywhere: 8
Gray-zone lymphoma between cHL and large B-cell lymphoma: a histopathologic series from the LYSA
C Sarkozy, C Copie-Bergman, D Damotte, S Ben-Neriah, B Burroni, ...
The American Journal of Surgical Pathology 43 (3), 341-351, 2019
Mandates: National Institute of Health and Medical Research, France
Comparison of EBV DNA viral load in whole blood, plasma, B‐cells and B‐cell culture supernatant
DE Ouedraogo, K Bollore, J Viljoen, V Foulongne, J Reynes, G Cartron, ...
Journal of medical virology 86 (5), 851-856, 2014
Mandates: Wellcome Trust
TRANSCEND FL: PHASE 2 STUDY RESULTS OF LISOCABTAGENE MARALEUCEL (LISO‐CEL) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL).
F Morschhauser, S Dahiya, ML Palomba, AM Garcia‐Sancho, JL Ortega, ...
Hematological Oncology 41, 2023
Mandates: European Commission
The influence of underlying disease on rituximab pharmacokinetics may be explained by target-mediated drug disposition
A Bensalem, G Cartron, U Specks, D Mulleman, E Gyan, D Cornec, ...
Clinical Pharmacokinetics 61 (3), 423-437, 2022
Mandates: US National Institutes of Health, Agence Nationale de la Recherche
MURANO: Final 7 year follow up and retreatment analysis in venetoclax‐rituximab (VenR)‐treated patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL).
AP Kater, R Harrup, TJ Kipps, B Eichhorst, CJ Owen, S Assouline, ...
Hematological Oncology 41, 2023
Mandates: US National Institutes of Health, State of Califonia
Scientific significance of clinically insignificant FcγRIIIa-V158F polymorphism
G Cartron, R Houot, HE Kohrt
Clinical Cancer Research 22 (4), 787-789, 2016
Mandates: Damon Runyon Cancer Research Foundation
Angiogenic factors could help us to define patients obtaining complete response with undetectable minimal residual disease in untreated CLL patients treated by FCR: results …
AL Gagez, F Paul, E Alaterre, V Gouilleux-Gruart, E Tuaillon, S Lepretre, ...
Leukemia & lymphoma 62 (13), 3160-3169, 2021
Mandates: Agence Nationale de la Recherche
IRONOMYCIN KILLS DIFFUSE LARGE B‐CELL LYMPHOMA CELLS BY TARGETING CELLULAR IRON HOMEOSTASIS
J Devin, T Cañeque, YL Lin, L Mondoulet, JL Veyrune, M Abouladzé, ...
Hematological Oncology 39, 2021
Mandates: National Institute of Health and Medical Research, France, European …
Available somewhere: 69
Rituximab plus lenalidomide in advanced untreated follicular lymphoma
F Morschhauser, NH Fowler, P Feugier, R Bouabdallah, H Tilly, ...
New England Journal of Medicine 379 (10), 934-947, 2018
Mandates: US National Institutes of Health, National Institute of Health and Medical …
A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies
HS Walter, SA Rule, MJS Dyer, L Karlin, C Jones, B Cazin, P Quittet, ...
Blood, The Journal of the American Society of Hematology 127 (4), 411-419, 2016
Mandates: Cancer Research UK
Venetoclax plus rituximab in relapsed chronic lymphocytic leukemia: 4-year results and evaluation of impact of genomic complexity and gene mutations from the MURANO phase III study
AP Kater, JQ Wu, T Kipps, B Eichhorst, P Hillmen, J D’rozario, S Assouline, ...
Journal of Clinical Oncology 38 (34), 4042-4054, 2020
Mandates: US National Institutes of Health, State of Califonia
T-cell defect in diffuse large B-cell lymphomas involves expansion of myeloid-derived suppressor cells
I Azzaoui, F Uhel, D Rossille, C Pangault, J Dulong, J Le Priol, T Lamy, ...
Blood, The Journal of the American Society of Hematology 128 (8), 1081-1092, 2016
Mandates: National Institute of Health and Medical Research, France
Venetoclax plus R-or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial
AD Zelenetz, G Salles, KD Mason, C Casulo, S Le Gouill, LH Sehn, H Tilly, ...
Blood, The Journal of the American Society of Hematology 133 (18), 1964-1976, 2019
Mandates: US National Institutes of Health
Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers
G Fossard, F Broussais, I Coelho, S Bailly, E Nicolas-Virelizier, ...
Annals of Oncology 29 (3), 715-723, 2018
Mandates: European Commission
Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial
J Trotman, SF Barrington, D Belada, M Meignan, R MacEwan, C Owen, ...
The Lancet Oncology 19 (11), 1530-1542, 2018
Mandates: Cancer Research UK, UK Engineering and Physical Sciences Research Council …
Circulating miRNA‐125b is a potential biomarker predicting response to rituximab in rheumatoid arthritis
I Duroux-Richard, YM Pers, S Fabre, M Ammari, D Baeten, G Cartron, ...
Mediators of inflammation 2014 (1), 342524, 2014
Mandates: National Institute of Health and Medical Research, France
Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab
JF Seymour, TJ Kipps, BF Eichhorst, J D’Rozario, CJ Owen, S Assouline, ...
Blood, The Journal of the American Society of Hematology 140 (8), 839-850, 2022
Mandates: US National Institutes of Health, State of Califonia
High efficiency cell-specific targeting of cytokine activity
G Garcin, F Paul, M Staufenbiel, Y Bordat, J Van der Heyden, S Wilmes, ...
Nature communications 5 (1), 1-9, 2014
Mandates: Research Foundation (Flanders)
Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions
CL Freeman, F Morschhauser, L Sehn, M Dixon, R Houghton, T Lamy, ...
Blood, The Journal of the American Society of Hematology 126 (24), 2646-2649, 2015
Mandates: US National Institutes of Health, German Research Foundation
A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL
N Schmitz, L Truemper, K Bouabdallah, M Ziepert, M Leclerc, G Cartron, ...
Blood, The Journal of the American Society of Hematology 137 (19), 2646-2656, 2021
Mandates: Federal Ministry of Education and Research, Germany
Publication and funding information is determined automatically by a computer program